|| Checking for direct PDF access through Ovid
Peritoneal carcinomatosis (PC) is a common manifestation of advanced malignancy, associated with a badprognosis. There is increasing interest in hyperthermic intraperitoneal chemotherapy (HIPEC) combined with surgical cytoreduction (SC). We report our experience of the management of peritoneal carcinomatosis, focusing on colorectal malignancy.Retrospective study of all operative management of PC by SC-HIPEC from 1996 to 2009.During this period, 60 surgical explorations for PC were performed. Complete SC was impossible in 9. Median age of the 51 resected patients (34F, 17M), was 50 (17-66). Primary cancers were 32% pseudomyxomas, 25% colorectal, 22% ovarian, 17% gastric and 4% mesotheliomas. Severe complication rate (grade III-IV) was of 39%; reoperation occured in 20% (three anastomotic leaks, four perforations); perioperative mortality (D60) was 2% (n = 1); median hospital stay was 30 days (12-105). Median follow-up was 18 months (1-196), with an overall survival rate of 80%. Colorectal disease showed a better survival than non colorectal malignancies (100% of survival in pseudomyxoma and 86% in adenocarcinoma)SC-HIPEC has aprofound impact on theprognosis of colorectal peritoneal carcinomatosis with better survival than for other malignancies. In this context, the high observed morbidity appears acceptable.